肝脏靶向RNA干扰在ZZ型α-1抗胰蛋白酶缺乏症患者中实现稳健持久的α-1抗胰蛋白酶水平敲低
这项双盲首次人体研究评估RNAi治疗药物ARC-AAT沉默α-1抗胰蛋白酶生成的效果。A部分54名健康志愿者接受0.38至8.0 mg/kg单次递增剂量或安慰剂;B部分11名PiZZ基因型患者接受最高4.0 mg/kg ARC-AAT或安慰剂。在≥4 mg/kg剂量下观察到血清AAT降低的剂量反应,4 mg/kg时健康志愿者最大降低76.1%、PiZZ患者降低78.8%;研究因非人灵长类研究中递送载体ARC-EX1相关毒性发现而提前终止。
要点
- 在≥4 mg/kg剂量下观察到血清AAT降低的剂量反应,健康志愿者与PiZZ患者相对降低幅度相似。
- 4 mg/kg剂量下血清AAT最大降低:健康志愿者76.1%,PiZZ患者78.8%。
- 研究因非人灵长类研究中递送载体ARC-EX1相关毒性发现而提前终止。
核心结论
- PiZZ患者与健康志愿者对ARC-AAT的反应相似。
- 基于观察到的血清AAT浓度降低,证实了对肝脏AAT生成的深度且持久的敲低。
研究设计与样本
- 双盲首次人体研究,分A、B两部分。
- A部分随机54名健康志愿者进入单次剂量队列(安慰剂:活性药=2:4),接受ARC-AAT 0.38至8.0 mg/kg递增剂量或安慰剂。
- B部分随机11名PiZZ基因型AATD患者,接受最高4.0 mg/kg ARC-AAT或安慰剂。
- 排除基线FibroScan® >11 kPa或第一秒用力呼气容积(FEV1)<60%的患者。
- 评估包括安全性、药代动力学和血清AAT浓度变化。
主要发现
- A部分36名健康志愿者接受ARC-AAT,18名接受安慰剂。
- B部分7名PiZZ个体接受ARC-AAT,4名接受安慰剂。
- 在≥4 mg/kg剂量下观察到血清AAT降低的剂量反应,4 mg/kg时PiZZ患者与健康志愿者相对降低幅度相似。
- 4 mg/kg剂量下血清AAT最大降低:健康志愿者76.1%,PiZZ患者78.8%。
- 血清AAT恢复至基线的时间在健康志愿者与PiZZ患者间相似,安全性参数无显著差异。
局限性
- 研究因非人灵长类研究中递送载体(ARC-EX1)相关毒性发现而提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder causing pulmonary and liver disease. The PiZ mutation in AAT (SERPINA1) results in mis-folded AAT protein (Z-AAT) accumulating in hepatocytes, leading to fibrosis and cirrhosis. RNAi-based therapeutics silencing production of hepatic Z-AAT might benefit patients with AATD-associated liver disease. This study evaluated an RNAi therapeutic to silence production of AAT. METHODS: Part A of this double-blind first-in-human study randomized 54 healthy volunteers (HVs) into single dose cohorts (two placebo: four active), receiving escalating doses of the investigational agent ARC-AAT from 0.38 to 8.0 mg/kg or placebo. Part B randomized 11 patients with PiZZ (homozygous for Z-AAT) genotype AATD, who received up to 4.0 mg/kg of ARC-AAT or placebo. Patients with baseline FibroScan® >11 kPa or forced expiratory volume in one second (FEV1) <60% were excluded. Assessments included safety, pharmacokinetics, and change in serum AAT concentrations. RESULTS: A total of 36 HVs received ARC-AAT and 18 received placebo (part A). Seven PiZZ individuals received ARC-AAT and four received placebo (part B). A dose response in serum AAT reduction was observed at doses ≥4 mg/kg with similar relative reductions in PiZZ patients and HVs at 4 mg/kg and a maximum reduction of 76.1% (HVs) vs. 78.8% (PiZZ) at this dose. The time it took for serum AAT to return to baseline was similar for HV and PiZZ. There were no notable differences between HV and PiZZ safety parameters. The study was terminated early because of toxicity findings related to the delivery vehicle (ARC-EX1) seen in a non-human primate study. CONCLUSION: PiZZ patients and HVs responded similarly to ARC-AAT. Deep and durable knockdown of hepatic AAT production based on observed reduction in serum AAT concentrations was demonstrated. LAY SUMMARY: Accumulation of abnormal proteins in the livers of patients with alpha-1 antitrypsin deficiency may lead to decreased liver function and potentially liver failure. Therapeutics targeting the production of these abnormal proteins may be used to prevent or treat liver disease in patients with alpha-1 antitrypsin deficiency. CLINICAL TRIAL REGISTRATION NUMBER: NCT02363946.
引用
- Turner AM, Stolk J, Bals R, et al. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol. 2018. PMID: 29572094. doi:10.1016/j.jhep.2018.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。